【摘要】 目的为临床肝移植患者抗移植排斥反应药物的合理应用提供参考。方法采用微粒子酶免疫法(MEIA)对肝移植患者进行他可莫司血药浓度测定,并对结果进行分析。结果为6例肝移植患者检测他可莫司血药浓度77例次,质控结果均在有效范围内。肝移植术后他可莫司全血血药浓度在10-20μg/L范围内的占30.6%。结论为用药安全有效,应对肝移植患者监测FK506血药浓度,实行个体化给药。更多还原

【Abstract】 Objective To give some information for rationally administrating oral FK506 to liver transplant patients in clinical.(Methods)The whole blood concentration of FK506 on 6 liver transplant patients was determined by mico-particle enzyme immunoassy(MEIA),the results and therapeutic effect were studied.Results There were 77 cases in 6 liver transplant patients determined FK506 concentration,the quality control of MEIA was in effective level.The whole blood with effective level(10-20μg/L) were accounted for 30.6%.Conclusion To be safe and effective for clinical use,it is important for liver transplant patients to monitor whole blood concentrations of FK506 with individualized drug administration.更多还原